The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

By T. Hideshima, P. Richardson, D. Chauhan, V. Palombella, P. Elliott, Julian Adams, K. Anderson. Cancer Research, 2001

1,616 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. (2005, background): “Bortezomib (VELCADE)(6) is the first proteasome inhibitor to enter clinical practice for the treatment of relapsed/refractory multiple myeloma (MM), based in part on pioneering preclinical studies.(7) Phase I-III trials showed bortezomib had impressive anti-myeloma activity (10), and additional stud”
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma (2004, background): “Application of bortezomib to either myeloma cell lines or cells freshly isolated from myeloma patients directly inhibited proliferation and induced apoptosis, regardless of p21, p27 or p53 expression (Hideshima et al, 2001).”
Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives (2011, background): “compared with peripheral blood mononuclear cells (PBMCs) from normal volunteers [53].”
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. (2010, background): “‡Numbers of patients with results for del 13q, del 17p, t(4;14), and t(11;14) status were 51, 50, 41, and 51, respectively, for the overall population, and 30, 30, 22, and 30 for the phase 2 population.”